Skip to content
mapperlab
← Dashboard
Stock

NBP

NovaBridge Biosciences
Latest close $1.713 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
3
27 funds tracked
Ever held
6
Current + past
New this quarter
2
Exited this quarter
1

Marquee-fund ownership over time

Aug 13, 2021Aug 14, 2024Nov 14, 2025May 15, 2026
Now
3

This quarter's activity

New positions opened

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$1.06$1.71+61%
Citadel Advisors re-entered$1.06$1.71+61%
Point72 Asset Management$4.15$1.71-59%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Millennium Management 2× in & out→ $1.82-56%
Two Sigma Investments→ $4.15+292%
Bridgewater Associates→ $2.54-96%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at NovaBridge Biosciences. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
2
Filings · last 90d
3
Total on file
3
Recent SEC buffer
Most recent
Jun 2, 2026

30d / 90d windows measured from Jun 2, 2026 — the most recent Form 4 on file — not from today.

Fundamentals

XBRL · NovaBridge Biosciences

Annual figures sourced directly from NovaBridge Biosciences's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$632K
FY2023+141% YoY
Net income
-$46.27M
FY2025-108% YoY
EPS (diluted)
$-0.2100
FY2025-75% YoY
Free cash flow(?)
-$183.96M
FY2023-14% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for NovaBridge Biosciences — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Citadel AdvisorsQ2 2026open$1.82$1.71-6%
Renaissance TechnologiesQ2 2026open$1.92$1.71-11%
Millennium ManagementQ4 2025Q2 2026$4.15$1.82-56%
Point72 Asset ManagementQ4 2025open$4.15$1.71-59%
Citadel AdvisorsQ3 2024Q2 2025$1.06$0.88-17%
Two Sigma InvestmentsQ3 2024Q4 2025$1.06$4.15+292%
Millennium ManagementQ3 2024Q3 2025$1.06$5.16+387%
Renaissance TechnologiesQ3 2024Q1 2026$1.06$3.24+206%
Bridgewater AssociatesQ3 2021Q3 2023$70$2.54-96%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.